(Q30828178)

15 September 2017

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort (English)

1 reference

15 September 2017

0 references

1 reference

1 reference

15 September 2017

Carolina Cimminiello

0 references

Lorenza Di Guardo

0 references

Jacopo Pigozzo

0 references

Michele Del Vecchio

0 references

Paola Queirolo

0 references

Paolo Marchetti

0 references

Massimo Aglietta

0 references

Paolo Antonio Ascierto

object named as

Paolo A Ascierto

1 reference

15 September 2017

Ester Simeone

1 reference

15 September 2017

Vanna Chiarion Sileni

1 reference

15 September 2017

Maresa Altomonte

1 reference

15 September 2017

Ruggero Ridolfi

1 reference

15 September 2017

Francesco Cognetti

1 reference

15 September 2017

Alessandro Testori

1 reference

15 September 2017

Maria Grazia Bernengo

1 reference

15 September 2017

Michele Guida

1 reference

15 September 2017

Riccardo Marconcini

1 reference

15 September 2017

Mario Mandalà

1 reference

15 September 2017

Gaetana Rinaldi

1 reference

15 September 2017

7 May 2014

1 reference

Journal of Translational Medicine

15 September 2017

1 reference

15 September 2017

1 reference

15 September 2017

116

1 reference

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma

15 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030525

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030525

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030525

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030525

Resistance to BRAF-targeted therapy in melanoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030525

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030525

Management of immune-related adverse events and kinetics of response with ipilimumab

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030525

Upcoming strategies for the treatment of metastatic melanoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030525

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030525

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030525

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030525

Targeting BRAF for patients with melanoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030525

Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030525

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030525

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030525

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030525

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4030525

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1479-5876-12-116

Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1479-5876-12-116

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1479-5876-12-116

21 January 2018

Identifiers

DOI

10.1186/1479-5876-12-116

1 reference

Dimensions Publication ID

15 September 2017

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/1479-5876-12-116

1 reference

15 September 2017

PubMed publication ID

24885479

1 reference